Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03901469 · ClinicalTrials.gov registry record · Phase 2
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
A Phase 2 study, sponsored by Zenith Epigenetics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT03901469: Clinical Trial Phase 2 study, sponsored by Zenith Epigenetics.
NCT03901469 is a Phase 2 study that was terminated before completion, run by Zenith Epigenetics. The registered enrollment target is 115 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03901469, a Phase 2 study, was terminated before completion, sponsored by Zenith Epigenetics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
This is a two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is a dose escalation and Part 2 is a Simon 2-Stage design. There are 3 expansion cohorts: Expansion Cohort A (combination treatment in post-TROP2-ADC patients), Expansion Cohort B (ZEN003694 monotherapy), and Expansion Cohort C (combination treatment in TROP2-ADC-naive patients).
Interventions
- DRUG Talazoparib
- DRUG ZEN003694
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2019-06-26 |
| Est. Completion | 2024-03-07 |
| Phase | Phase 2 |
Why NCT03901469 stopped before completion
NCT03901469 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower).
The record links to 0 conditions, and to 2 interventions - of which Talazoparib is the first listed.
NCT03901469 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03901469 about?
NCT03901469 is a clinical study titled "A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer". This is a two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is a dose escalation and Part 2 is a Simon 2-Stage design. There are 3 expansion cohorts: Expansion Cohort A (combinat...
What is the current status of trial NCT03901469?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2019-06-26. Estimated completion is 2024-03-07.
What interventions are being tested in trial NCT03901469?
The interventions under investigation include: Talazoparib (DRUG), ZEN003694 (DRUG).
Who is sponsoring clinical trial NCT03901469?
This trial is sponsored by Zenith Epigenetics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03901469's enrollment target sits among peer trials
115 626th of 2000 higher than 1,374 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI